Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by ALEXANDER LAZAR and CHRISTINA LYNN ROLAND.
ALEXANDER LAZAR
Connection Strength
2.675
CHRISTINA LYNN ROLAND
  1. A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma. Nat Cancer. 2024 Apr; 5(4):625-641.
    View in: PubMed
    Score: 0.235
  2. Sentinel Lymph Node Biopsy for Extremity and Truncal Soft Tissue Sarcomas: A Systematic Review of the Literature. Ann Surg Oncol. 2023 Feb; 30(2):958-967.
    View in: PubMed
    Score: 0.215
  3. Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. BMC Cancer. 2018 Sep 24; 18(1):913.
    View in: PubMed
    Score: 0.162
  4. Identification of preoperative factors associated with outcomes following surgical management of intra-abdominal recurrent or metastatic GIST following neoadjuvant tyrosine kinase inhibitor therapy. J Surg Oncol. 2018 Apr; 117(5):879-885.
    View in: PubMed
    Score: 0.155
  5. Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy. Oncoimmunology. 2018; 7(2):e1385689.
    View in: PubMed
    Score: 0.152
  6. Myxofibrosarcoma. Surg Oncol Clin N Am. 2016 10; 25(4):775-88.
    View in: PubMed
    Score: 0.139
  7. Clinical Observations and Molecular Variables of Primary Vascular Leiomyosarcoma. JAMA Surg. 2016 Apr; 151(4):347-54.
    View in: PubMed
    Score: 0.136
  8. Analysis of Clinical and Molecular Factors Impacting Oncologic Outcomes in Undifferentiated Pleomorphic Sarcoma. Ann Surg Oncol. 2016 07; 23(7):2220-8.
    View in: PubMed
    Score: 0.135
  9. Plasma DNA Methylation-Based Biomarkers for MPNST Detection in Patients With Neurofibromatosis Type 1. Mol Carcinog. 2025 Jan; 64(1):44-56.
    View in: PubMed
    Score: 0.062
  10. Patterns of Care and Outcomes of Patients with Small Gastrointestinal Stromal Tumors at a High-Volume Sarcoma Center. Ann Surg Oncol. 2024 Dec; 31(13):9258-9264.
    View in: PubMed
    Score: 0.061
  11. Clinical Variables Influencing Outcomes in Patients with Atypical Intradermal Smooth Muscle Neoplasms (Formerly Cutaneous Leiomyosarcomas): Single-Institution Study of 95 Surgical Patients. Ann Surg Oncol. 2024 Nov; 31(12):7950-7956.
    View in: PubMed
    Score: 0.061
  12. Clinical characteristics and outcomes of adult alveolar rhabdomyosarcoma patients on first-line systemic therapies: A single-institution cohort. Rare Tumors. 2024; 16:20363613241271669.
    View in: PubMed
    Score: 0.061
  13. Current Management of Desmoid Tumors: A Review. JAMA Oncol. 2024 Aug 01; 10(8):1121-1128.
    View in: PubMed
    Score: 0.061
  14. Loss of the DNA Repair Gene RNase H2 Identifies a Unique Subset of DDR-Deficient Leiomyosarcomas. Mol Cancer Ther. 2024 Jul 02; 23(7):1057-1065.
    View in: PubMed
    Score: 0.060
  15. High-Grade Pleomorphic Sarcomas Treated with Immune Checkpoint Blockade: The MD Anderson Cancer Center Experience. Cancers (Basel). 2024 May 01; 16(9).
    View in: PubMed
    Score: 0.060
  16. Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101). Clin Cancer Res. 2023 05 01; 29(9):1708-1718.
    View in: PubMed
    Score: 0.056
  17. Targeting the Molecular and Immunologic Features of Leiomyosarcoma. Cancers (Basel). 2023 Mar 31; 15(7).
    View in: PubMed
    Score: 0.055
  18. The immune landscape of undifferentiated pleomorphic sarcoma. Front Oncol. 2022; 12:1008484.
    View in: PubMed
    Score: 0.054
  19. Re-excision After Unplanned Excision of Soft Tissue Sarcoma is Associated with High Morbidity and Limited Pathologic Identification of Residual Disease. Ann Surg Oncol. 2023 Jan; 30(1):480-489.
    View in: PubMed
    Score: 0.053
  20. Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial. Lancet Oncol. 2022 09; 23(9):1156-1166.
    View in: PubMed
    Score: 0.053
  21. Real-world use of palbociclib monotherapy in retroperitoneal liposarcomas at a large volume sarcoma center. Int J Cancer. 2022 06 15; 150(12):2012-2024.
    View in: PubMed
    Score: 0.051
  22. Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated state. Acta Neuropathol. 2021 09; 142(3):565-590.
    View in: PubMed
    Score: 0.049
  23. Comparison of Cancer Prevalence in Patients With Neurofibromatosis Type 1 at an Academic Cancer Center vs in the General Population From 1985 to 2020. JAMA Netw Open. 2021 03 01; 4(3):e210945.
    View in: PubMed
    Score: 0.048
  24. Evaluating the Soft Tissue Sarcoma Paradigm for the Local Management of Extraskeletal Ewing Sarcoma. Oncologist. 2021 03; 26(3):250-260.
    View in: PubMed
    Score: 0.047
  25. Certain risk factors for patients with desmoid tumors warrant reconsideration of local therapy strategies. Cancer. 2020 07 15; 126(14):3265-3273.
    View in: PubMed
    Score: 0.045
  26. B cells are associated with survival and immunotherapy response in sarcoma. Nature. 2020 01; 577(7791):556-560.
    View in: PubMed
    Score: 0.044
  27. Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab. Clin Cancer Res. 2020 03 15; 26(6):1258-1266.
    View in: PubMed
    Score: 0.044
  28. Extraskeletal Myxoid Chondrosarcomas: Combined Modality Therapy With Both Radiation and Surgery Improves Local Control. Am J Clin Oncol. 2019 10; 42(10):744-748.
    View in: PubMed
    Score: 0.043
  29. The degree of sclerosis is associated with prognosis in well-differentiated liposarcoma of the retroperitoneum. J Surg Oncol. 2019 Sep; 120(3):382-388.
    View in: PubMed
    Score: 0.043
  30. MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma. Cancers (Basel). 2019 May 15; 11(5).
    View in: PubMed
    Score: 0.042
  31. Extraskeletal Osteosarcomas: A Case Made for Combined Modality Local Therapy With Radiation and Surgery. Am J Clin Oncol. 2019 03; 42(3):238-242.
    View in: PubMed
    Score: 0.042
  32. Long-Term Outcomes for Patients With Desmoid Fibromatosis Treated With Radiation Therapy: A 10-Year Update and Re-evaluation of the Role of Radiation Therapy for Younger Patients. Int J Radiat Oncol Biol Phys. 2019 04 01; 103(5):1167-1174.
    View in: PubMed
    Score: 0.041
  33. Genomic profiling of dedifferentiated liposarcoma compared to matched well-differentiated liposarcoma reveals higher genomic complexity and a common origin. Cold Spring Harb Mol Case Stud. 2018 04; 4(2).
    View in: PubMed
    Score: 0.039
  34. Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes. Clin Sarcoma Res. 2017; 7:11.
    View in: PubMed
    Score: 0.037
  35. Radiation-Associated Undifferentiated Pleomorphic Sarcoma is Associated with Worse Clinical Outcomes than Sporadic Lesions. Ann Surg Oncol. 2015 Nov; 22(12):3913-20.
    View in: PubMed
    Score: 0.032
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.